Is autoimmunity coming to a Fas(t) end?
Brunner
T
T
Mueller
C
C
D000818:Animals; D017209:Apoptosis; D001169:Arthritis, Experimental / Q000276:immunology / Q000628:therapy; D001327:Autoimmune Diseases / Q000628:therapy*; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology / Q000628:therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D008301:Maleimides / Q000627:therapeutic use*; D051379:Mice; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D051381:Rats; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D019014:fas Receptor / Q000276:immunology*
D004791:Enzyme Inhibitors; D007211:Indoles; D008301:Maleimides; D019014:fas Receptor; D011493:Protein Kinase C; C088060:bisindolylmaleimide